Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Clinical Outcomes and Cost of Gram Negative Bacteremia
Epidemiology, Outcomes, and Costs Associated With Gram Negative Bacteremia
Status: Enrolling
Updated:  11/5/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Clinical Outcomes and Cost of Gram Negative Bacteremia
Epidemiology, Outcomes, and Costs Associated With Gram Negative Bacteremia
Status: Enrolling
Updated: 11/5/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Status: Enrolling
Updated:  11/6/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Status: Enrolling
Updated: 11/6/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Status: Enrolling
Updated:  11/6/2015
Mount Sinai School of Medicine - Tisch Cancer Institute
mi
from
New York, NY
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Status: Enrolling
Updated: 11/6/2015
Mount Sinai School of Medicine - Tisch Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Status: Enrolling
Updated:  11/6/2015
University of California at San Francisco
mi
from
San Francisco, CA
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Status: Enrolling
Updated: 11/6/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
Berkeley, CA
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
Berkeley, CA
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
San Francisco, CA
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
Augusta, GA
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
Augusta, GA
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
Baltimore, MD
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
Boston, MA
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
Omaha, NE
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
New York, NY
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
Winston Salem, NC
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
Winston Salem, NC
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
Pittsburgh, PA
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/6/2015
Local Institution
mi
from
Columbia, SC
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/6/2015
Local Institution
mi
from
Columbia, SC
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Northwestern University CRS (2701)
mi
from
Chicago, IL
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
mi
from
Boston, MA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
mi
from
Boston, MA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Henry Ford Hosp. CRS (31472)
mi
from
Detroit, MI
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Henry Ford Hosp. CRS (31472)
mi
from
Detroit, MI
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Washington U CRS (2101)
mi
from
St. Louis, MO
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Washington U CRS (2101)
mi
from
St. Louis, MO
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Cooper Univ. Hosp. CRS (31476)
mi
from
Camden, NJ
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Cooper Univ. Hosp. CRS (31476)
mi
from
Camden, NJ
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Cornell CRS (7804)
mi
from
New York, NY
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Cornell CRS (7804)
mi
from
New York, NY
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
NY Univ. HIV/AIDS CRS (401)
mi
from
New York, NY
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
NY Univ. HIV/AIDS CRS (401)
mi
from
New York, NY
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Unc Aids Crs
mi
from
Chapel Hill, NC
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Duke Univ. Med. Ctr. Adult CRS (1601)
mi
from
Durham, NC
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Duke Univ. Med. Ctr. Adult CRS (1601)
mi
from
Durham, NC
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Metro Health CRS (2503)
mi
from
Cleveland, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Metro Health CRS (2503)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Case CRS (2501)
mi
from
Cleveland, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Case CRS (2501)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Pitt CRS (1001)
mi
from
Pittsburgh, PA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Pitt CRS (1001)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
mi
from
Richmond, VA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
mi
from
Richmond, VA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
31788 Alabama CRS
mi
from
Birmingham, AL
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
31788 Alabama CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Wayne State Univ. CRS (31478)
mi
from
Detroit, MI
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Wayne State Univ. CRS (31478)
mi
from
Detroit, MI
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
New Jersey Medical School-Adult Clinical Research Ctr. CRS (31486)
mi
from
Newark, NJ
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
New Jersey Medical School-Adult Clinical Research Ctr. CRS (31486)
mi
from
Newark, NJ
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
AIDS Care CRS (1101)
mi
from
Rochester, NY
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
AIDS Care CRS (1101)
mi
from
Rochester, NY
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
mi
from
Rochester, NY
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
mi
from
Rochester, NY
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Click here to add this to my saved trials
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Kansas City, MO
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
New York, NY
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials